热景生物：参股公司SGC001创新药I期临床研究进展顺利

Core Viewpoint - The company has received an update on the progress of its innovative drug SGC001 injection from its associate Beijing ShunJing Biopharmaceutical Technology Co., Ltd, indicating positive advancements in clinical trials [1] Group 1: Clinical Research Progress - The SGC001 injection has completed Phase Ia clinical research with healthy volunteers [1] - The Phase Ib clinical research for patients with anterior ST-segment elevation myocardial infarction is progressing smoothly, with all subjects' clinical observations completed and data locked and unblinded [1] Group 2: Safety and Efficacy - SGC001 injection has shown good safety and tolerability in both healthy volunteers and patients with anterior ST-segment elevation myocardial infarction [1] - In the Phase Ib clinical study, no grade 3 or higher adverse events occurred across low (300 mg), medium (600 mg), and high (900 mg) dosage groups, and no serious adverse events were reported [1] - Preliminary analysis indicates that the initial efficacy results for SGC001 in patients with anterior ST-segment elevation myocardial infarction are generally in line with expectations, with statistical analysis and report summarization currently underway [1]